📰 Ongoing Phase News
Page 7 - Ongoing Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ongoing Phase. Real-time updates on events, politics, business and more.
June 8, 2022
Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...
June 6, 2022
06.06.2022 - - Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment - - Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date - SAN ... Seite 1
June 5, 2022
- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Dur
June 2, 2022
Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis
June 2, 2022
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...
May 31, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
May 27, 2022
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...
May 12, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
May 10, 2022
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease ... | May 10, 2022
May 4, 2022
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace